Search Results - "MacLeish, Sarah A."
-
1
Expanding the horizon of continuous glucose monitoring into the future of pediatric medicine
Published in Pediatric research (21-09-2024)“…Glucose monitoring has rapidly evolved with the development of minimally invasive continuous glucose monitoring (CGM) using interstitial fluid. It is…”
Get full text
Journal Article -
2
Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes
Published in Diabetes care (01-07-2021)“…Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet the burden of disease is significant. We report on a pivotal…”
Get full text
Journal Article -
3
1172-P: The Social Impact of COVID-19 Pandemic on Children with Diabetes
Published in Diabetes (New York, N.Y.) (20-06-2023)“…Aims: The aim of the study was to evaluate the social impact of the COVID-19 pandemic on youth with diabetes in Northeast Ohio from March 2020 through October…”
Get full text
Journal Article -
4
903-P: Switch from Insulin Glargine to Degludec in a Pediatric Population with T1D Leads to Decrease in DKA but No Change in Glycemic Control: A Retrospective Review
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Objective: Insulin degludec (IDeg) is an ultra-long acting insulin that gives more flexibility with dose timing. Studies comparing the efficacy of IDeg to…”
Get full text
Journal Article -
5
Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
Published in Diabetes care (01-08-2022)“…Very young children with type 1 diabetes often struggle to achieve glycemic targets, putting them at risk for long-term complications and creating an immense…”
Get full text
Journal Article -
6
How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System
Published in Diabetes research and clinical practice (01-08-2022)“…•Adults with T1D used an investigational tubeless Omnipod 5 AID system for 3 months.•Participants saw improvements in diabetes-related psychosocial outcomes…”
Get full text
Journal Article -
7
704-P: Adults with Type 1 Diabetes Report Improved Quality of Life with the Omnipod 5 Automated Insulin Delivery System
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Type 1 diabetes (T1D) can lead to significant emotional distress and impaired quality of life (QoL). Hybrid closed-loop (HCL) technology seeks to relieve this…”
Get full text
Journal Article -
8
71-OR: Youth with Type 1 Diabetes and Their Parents Report Improved Quality of Life with the Omnipod 5 Automated Insulin Delivery System
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Type 1 diabetes (T1D) can lead to significant emotional distress and impair quality of life (QoL). Hybrid closed-loop (HCL) technology seeks to relieve this…”
Get full text
Journal Article -
9
709-P: Improved Satisfaction and Perceived Usability with the Omnipod 5 Automated Insulin Delivery System Compared with Prior Therapy
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Type 1 diabetes (T1D) is a lifelong disease that requires constant monitoring. New technologies seeking to relieve this burden must be user-friendly and…”
Get full text
Journal Article -
10
33-OR: ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System
Published in Diabetes (New York, N.Y.) (01-06-2022)“…The Omnipod 5 AID System is a tubeless hybrid closed-loop system with on-body operation and customizable glucose targets. Safe and effective system use was…”
Get full text
Journal Article -
11
Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes
Published in Diabetes, obesity & metabolism (01-12-2024)“…Aim Automated insulin delivery (AID) systems have demonstrated improved glycaemic outcomes in people with type 1 diabetes (T1D), yet limited data exist on…”
Get full text
Journal Article -
12
1291-P: Characterization of Gut Microbiota in Lean Type 1 Diabetes, Overweight Type 1 Diabetes, and Healthy Controls
Published in Diabetes (New York, N.Y.) (01-06-2020)“…Background: The incidence of type 1 diabetes (T1D) and overweight/obesity is on the rise. Previous studies showed altered gut microbiota in children with T1D…”
Get full text
Journal Article -
13
554-P: Diabetes Distress in Young Adults with Youth-Onset Type 2 Diabetes: TODAY Study Results
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Aims: Diabetes distress (DD) is associated with poor health outcomes. Little is known about level of DD in young adults (YAs) with youth-onset type 2 diabetes…”
Get full text
Journal Article -
14
70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D)
Published in Diabetes (New York, N.Y.) (01-06-2021)“…The Omnipod 5 System is a novel hybrid closed-loop (HCL) system with full on-body operation. A tubeless insulin pump containing a personalized MPC algorithm…”
Get full text
Journal Article -
15
759-P: Glycemic Outcomes over 15 Months with the Omnipod 5 Automated Insulin Delivery System
Published in Diabetes (New York, N.Y.) (01-06-2022)“…Safe and effective use of the Omnipod 5 Automated Insulin Delivery (AID) System was demonstrated in adults and children with type 1 diabetes (T1D) during a…”
Get full text
Journal Article -
16
766-P: Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System Stratified by Baseline Hypoglycemia Risk among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
Published in Diabetes (New York, N.Y.) (01-06-2022)“…Hypoglycemia remains a major concern for persons with T1D using injections or “open loop” insulin pump delivery. Risk avoidance strategies are required, but…”
Get full text
Journal Article -
17
765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
Published in Diabetes (New York, N.Y.) (01-06-2022)“…AID systems must accommodate a wide range of insulin requirements safely and effectively to apply to a broad population. We evaluated glycemic outcomes among…”
Get full text
Journal Article -
18
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
Published in Diabetes technology & therapeutics (01-01-2024)“…The Omnipod 5 Automated Insulin Delivery (AID) System was shown to be safe and effective following 3 months of use in people with type 1 diabetes (T1D);…”
Get more information
Journal Article -
19
716-P: Transition from Multiple Daily Injections (MDI) to Omnipod 5 Automated Insulin Delivery System Improves A1C in Type 1 Diabetes (T1D)
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Many of those with T1D in the US use MDI as their insulin delivery method. Hybrid closed-loop (HCL) systems such as the Omnipod 5 System may improve glycemic…”
Get full text
Journal Article -
20
96-LB: Glycemic Management over 6 Months with the Omnipod 5 Automated Insulin Delivery System
Published in Diabetes (New York, N.Y.) (01-06-2021)“…Safe and effective use of the Omnipod 5 System was demonstrated in adults and children with type 1 diabetes (T1D) during a 3-month pivotal study. Longer…”
Get full text
Journal Article